Liver cancer
Results
Phase 1
This study looked at how safe a drug called ADP-A2AFP was for liver cancer. It also looked at how well it worked.
It was for people who had a cancer that started in the liver. This is called a of the liver. Everyone taking part had already had treatment but their cancer got worse.
The study was open for people to join between 2017 and 2021. The team reported the results in 2024.
Recruitment start: 1 June 2017
Recruitment end: 31 December 2021
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Tim Myer
Adaptimmune LLC
Last reviewed: 14 Mar 2025
CRUK internal database number: 15505
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
